Rise in Intercept Shares May be Attributed to Report of 'A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis'
Get News First. Profit Faster
With Benzinga Professional get unlimited access to ALL content! PLUS:
- REALTIME NEWSFEED
- REALTIME AUDIO NEWS
- FULL CALENDAR SUITE
- CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.